Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics

Satoshi Yamasaki, Goichi Yoshimoto, Ryosuke Ogawa, Kenichi Aoki, Masakazu Higuchi, Naoki Harada, Fumito Arima, Seiji Kondo, Fujio Matubara, Tsutomu Takahashi, Naokuni Uike, Toshihiro Miyamoto, Seiichi Okamura, Koichi Akashi

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

The introduction of reduced-intensity conditioning (RIC) regimens has made possible allogeneic hematopoietic cell transplantation (allo-HCT) in older patients with acute myeloid leukemia (AML). However, the optimal timing of allo-HCT in these patients and its relative risks and benefits when compared with chemotherapies have not been determined. This retrospective study by the Fukuoka Blood and Marrow Transplant Group compared RIC allo-HSCT with non-transplant therapies, the choice based on donor availability, in AML patients in their first complete remission (CR1). The prognostic value of various patient characteristics and disease-specific variables were investigated in 299 patients aged ≥60 years with AML in CR1. Among the 107 patients aged 60–65 years, 54 of whom received allo-HCT and 53 of whom continued chemotherapies; allo-HCT, adverse-risk group, and hematopoietic cell transplantation-comorbidity index were significant predictors of survival outcomes. Among 192 patients aged ≥66 years deemed ineligible for allo-HCT, relapse and Karnofsky performance status after induction therapy were significant predictors of survival outcomes. Findings from this study may facilitate a new standard of care for older AML patients in CR1 who are considered candidates for allo-HCT.

Original languageEnglish
Pages (from-to)1159-1165
Number of pages7
JournalAnnals of Hematology
Volume94
Issue number7
DOIs
Publication statusPublished - Jul 18 2015

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Factors prognostic of eligibility for allogeneic HCT among older patients with AML-CR1 and adverse- or intermediate-risk cytogenetics'. Together they form a unique fingerprint.

Cite this